| Filed On | Filing |
|---|---|
| 13 Dec 2021 |
8-K/A: Other Events
Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition |
Loading...